December 22, 2025—iVascular announced the initiation of the 4-NiVO clinical study, which is evaluating the efficacy and safety of its iNstroke 4 ...

Jaypirca achieved non-inferiority to Imbruvica in overall response rate, with an 87% response compared to 78.5% for Imbruvica. The trial indicated favorable progression-free survival trends for ...

The shingles vaccine not only offers protection against the painful viral infection, a new study suggests that the two-dose shot also may slow the progression of dementia. Shingles, caused by the ...

BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed ...

Oct 28 (Reuters) - Merck (MRK.N), opens new tab and Eisai's (4523.T), opens new tab experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-approved indications, the drug is showing it still has unfinished business. In the ...

Harmony Biosciences shares slumped after the pharmaceutical company's late-stage trial of proposed treatment for rare genetic disorder Fragile X syndrome failed to meet its main goal. Harmony on ...

Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with ...

Regeneron Pharmaceuticals said a late-stage study of its investigational drug garetosmab met its key goal in the ultra-rare genetic disorder fibrodysplasia ossificans progressiva, or FOP. Regeneron on ...